Compare Microsoft (MSFT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Twist Bioscience Corp — how do they compare? Microsoft trades at $532.44 (market cap $3.88T), while Twist Bioscience Corp trades at $166.78 (market cap $10.08B). The key difference: Microsoft is far larger — about 384.9× Twist Bioscience Corp's market cap, and Microsoft pays a 0.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Twist Bioscience Corp for 27 Days on average.
| MSFT | TWST | |
|---|---|---|
Market Cap | $3.88T | $10.08B |
Volume | 19,593,392 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $542.07 | $205.00 |
52-Week Low | $352.83 | $25.45 |
Typical Hold Time | 142 Days | 27 Days |
Enterprise Value | $3.86T | $10.01B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft trades at $529.76, up 0.09% with strong bullish technical signals and consistent earnings beats. The company maintains robust fundamentals with $281.72B revenue, 40.31% net margin, and positive cash flow. Recent analyst coverage shows 82% buy ratings with a $571.76 consensus target, while technical indicators suggest support at $526 and resistance at $533.
Outlook remains positive with AI leadership driving growth, though elevated P/E of 29.11 and competitive pressures present risks. The stock offers solid dividend income and institutional support, but investors should monitor capital expenditure trends and market rotation away from mega-cap tech stocks.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
